Sort
82,697 grants matching “vaccine development”
Glycolipid Presentation by CD1d
$1,315,584Albert S. Bendelac · University Of Chicago · P01 · FY2009 · AI
Task C13: Production and Distribution of Filarial Research Reagents
$1,315,567Andrew Ridell · University Of Georgia · N01 · FY2022 · AI
CAP-IT Center for LNP RNA Immunoprevention
$1,315,413Vivek Mittal · Weill Medical Coll Of Cornell Univ · U54 · FY2025 · CA
MICROBIOLOGY AND INFECTIOUS DISEASES BIOLOGICAL RESOURCE REPOSITORY (MID-BRR)
$1,315,404James McArdle · American Type Culture Collection · N01 · FY2010 · AI
Advancing a second generation C. difficile vaccine
$1,315,168Mark L Lang · University Of Oklahoma Hlth Sciences Ctr · U19 · FY2024 · AI
Advancing a second generation C. difficile vaccine
$1,315,168Mark L Lang · University Of Oklahoma Hlth Sciences Ctr · U19 · FY2025 · AI
Advancing a second generation C. difficile vaccine
$1,315,168Mark L Lang · University Of Oklahoma Hlth Sciences Ctr · U19 · FY2023 · AI
Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant.
$1,315,127B. Kim Lee Sim · Sanaria, Inc. · U01 · FY2021 · AI
NIAID Centers of Excellence for Influenza Research and Response
$1,314,244S. Mark Tompkins · University Of Georgia · N01 · FY2024 · AI
Immunotherapy to prevent drug-resistant tuberculosis
$1,314,028Rhea N Coler · Access To Advanced Health Institute · R01 · FY2017 · AI
Conjugate vaccines for prevention and treatment of cryptococcosis - COVID-19 Revision Supplement
$1,313,891Arturo Casadevall · Johns Hopkins University · R01 · FY2020 · AI
Disseminated Tuberculosis in HIV Infection
$1,313,181C. Fordham Von Reyn · Dartmouth College · U01 · FY2007 · AI
Development of Improved DNA Vaccines and Electroporation Delivery Devices for HIV
$1,312,685Niranjan Sardesai · Viral Genomix, Inc. · N01 · FY2013 · AI
The Danger Model 2: how tissues control Immunity
$1,312,470Polly C Matzinger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Studies of Receptor Interactions and Effects of Alarmins
$1,311,888Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Immunity to Pulmonary Infections
$1,311,686Catharine Bosio · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana
$1,311,671Roger L Shapiro · Harvard University D/B/A Harvard School Of Public Health · U01 · FY2025 · AI
Medicinal Chemistry of Drugs Acting on Central and Peripheral Opioid Receptors
$1,311,436Kenner Rice · National Institute On Drug Abuse · ZIA · FY2015 · DA
Clinical Research Support for the CCR
$1,311,425Thomas A Misteli · Division Of Basic Sciences - Nci · ZID · FY2017 · CA
The Initiation of B-Cell Signaling
$1,311,151Susan Pierce · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
PEDIATRIC AIDS CLINICAL TRIALS UNIT
$1,310,981Children'S Memorial Hospital (Chicago) · U01 · FY2001 · AI
Probiotics to Enhance Influenza Vaccine Immunogenicity
$1,310,980Patricia L Hibberd · Massachusetts General Hospital · U01 · FY2010 · AT
RFA-IP-22-004, Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027
$1,310,713Karen J Wernli · Kaiser Foundation Health Plan Of Washington · U01 · FY2025 · IP
RFA-IP-22-004:Michigan-Ford Initiative to Measure Vaccine Effectiveness (MFIVE): Seasonal Influenza, COVID-19 and Respiratory Virus Vaccines
$1,310,713Emily Toth Martin · University Of Michigan At Ann Arbor · U01 · FY2025 · IP
Enhancing B cell immunity against HIV-1 using novel vaccine delivery platforms
$1,310,664Michael W Cho · Iowa State University · U19 · FY2010 · AI